249 related articles for article (PubMed ID: 34615471)
1. Associations of the cerebrospinal fluid hepatocyte growth factor with Alzheimer's disease pathology and cognitive function.
Zhao LJ; Wang ZT; Ma YH; Zhang W; Dong Q; Yu JT; Tan L;
BMC Neurol; 2021 Oct; 21(1):387. PubMed ID: 34615471
[TBL] [Abstract][Full Text] [Related]
2. Associations of cerebrospinal fluid complement proteins with Alzheimer's pathology, cognition, and brain structure in non-dementia elderly.
Li M; Ma YH; Guo Y; Liu JY; Tan L;
Alzheimers Res Ther; 2024 Jan; 16(1):12. PubMed ID: 38238858
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
[TBL] [Abstract][Full Text] [Related]
4. Associations of Alcohol Consumption with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study.
Wang ZT; Li KY; Tan CC; Xu W; Shen XN; Cao XP; Wang P; Bi YL; Dong Q; Tan L; Yu JT
J Alzheimers Dis; 2021; 82(3):1045-1054. PubMed ID: 34151793
[TBL] [Abstract][Full Text] [Related]
5. Influence of plasma matrix metalloproteinase levels on longitudinal changes in Alzheimer's disease (AD) biomarkers and cognitive function in patients with mild cognitive impairment due to AD registered in the Alzheimer's Disease Neuroimaging Initiative database.
Abe K; Chiba Y; Hattori S; Yoshimi A; Asami T; Katsuse O; Suda A; Hishimoto A;
J Neurol Sci; 2020 Sep; 416():116989. PubMed ID: 32603972
[TBL] [Abstract][Full Text] [Related]
6. A study of the longitudinal changes in multiple cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers on converter and non-converter Alzheimer's disease subjects with consideration for their amyloid beta status.
Morar U; Izquierdo W; Martin H; Forouzannezhad P; Zarafshan E; Unger E; Bursac Z; Cabrerizo M; Barreto A; Vaillancourt DE; DeKosky ST; Loewenstein D; Duara R; Adjouadi M
Alzheimers Dement (Amst); 2022; 14(1):e12258. PubMed ID: 35229014
[TBL] [Abstract][Full Text] [Related]
7. Association of Subjective Cognitive Decline with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study.
Wen C; Bi YL; Hu H; Huang SY; Ma YH; Hu HY; Tan L; Yu JT
J Alzheimers Dis; 2022; 85(3):1143-1151. PubMed ID: 34924386
[TBL] [Abstract][Full Text] [Related]
8. Association of CSF GAP-43 With the Rate of Cognitive Decline and Progression to Dementia in Amyloid-Positive Individuals.
Öhrfelt A; Benedet AL; Ashton NJ; Kvartsberg H; Vandijck M; Weiner MW; Trojanowski JQ; Shaw LM; Zetterberg H; Blennow K;
Neurology; 2023 Jan; 100(3):e275-e285. PubMed ID: 36192174
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal Fluid Complement 4 Levels Were Associated with Alzheimer's Disease Pathology and Cognition in Non-Demented Elderly.
Zhou J; Wang ZB; Sun Y; Fu Y; Li D; Tan L;
J Alzheimers Dis; 2023; 96(3):1071-1081. PubMed ID: 38007670
[TBL] [Abstract][Full Text] [Related]
10. Peripheral Markers of Vascular Endothelial Dysfunction Show Independent but Additive Relationships with Brain-Based Biomarkers in Association with Functional Impairment in Alzheimer's Disease.
Drake JD; Chambers AB; Ott BR; Daiello LA;
J Alzheimers Dis; 2021; 80(4):1553-1565. PubMed ID: 33720880
[TBL] [Abstract][Full Text] [Related]
11. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
[TBL] [Abstract][Full Text] [Related]
12. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
13. Association between CSF Aβ42 and amyloid negativity in patients with different stage mild cognitive impairment.
He B; Wang L; Xu B; Zhang Y;
Neurosci Lett; 2021 May; 754():135765. PubMed ID: 33667602
[TBL] [Abstract][Full Text] [Related]
14. CAIDE Score, Alzheimer's Disease Pathology, and Cognition in Cognitively Normal Adults: The CABLE Study.
Guo ZX; Liu F; Wang FY; Ou YN; Huang LY; Hu H; Wang ZB; Fu Y; Gao PY; Tan L; Yu JT
J Alzheimers Dis; 2024; 99(4):1273-1283. PubMed ID: 38728186
[TBL] [Abstract][Full Text] [Related]
15. Clinical Experience with Cerebrospinal Fluid Aβ42, Total and Phosphorylated Tau in the Evaluation of 1,016 Individuals for Suspected Dementia.
Tariciotti L; Casadei M; Honig LS; Teich AF; McKhann Ii GM; Tosto G; Mayeux R
J Alzheimers Dis; 2018; 65(4):1417-1425. PubMed ID: 30149454
[TBL] [Abstract][Full Text] [Related]
16. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
[TBL] [Abstract][Full Text] [Related]
18. A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment.
Wang H; Stewart T; Toledo JB; Ginghina C; Tang L; Atik A; Aro P; Shaw LM; Trojanowski JQ; Galasko DR; Edland S; Jensen PH; Shi M; Zhang J;
J Alzheimers Dis; 2018; 61(4):1541-1553. PubMed ID: 29376878
[TBL] [Abstract][Full Text] [Related]
19. Associations between liver function and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in non-demented adults: The CABLE study.
Gao PY; Ou YN; Huang YM; Wang ZB; Fu Y; Ma YH; Li QY; Ma LY; Cui RP; Mi YC; Tan L; Yu JT
J Neurochem; 2024 Jan; 168(1):39-51. PubMed ID: 38055867
[TBL] [Abstract][Full Text] [Related]
20. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
